Reducing Infection Susceptibility by Immune Function Restoration in Spinal Cord Injury
通过恢复脊髓损伤的免疫功能来降低感染易感性
基本信息
- 批准号:10656433
- 负责人:
- 金额:$ 36.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAcute PneumoniaAddressAdrenal Gland HyperfunctionAdrenal GlandsAnatomyAnti-Infective AgentsAntibiotic ResistanceAntibiotic TherapyAntibioticsApplications GrantsAtrophicAutonomic DysfunctionBacteriaBacterial PneumoniaBiological AssayBiological MarkersCatecholaminesCause of DeathCellsCessation of lifeCharacteristicsClinicalColony-forming unitsComplementCre lox recombination systemDataDevelopmentDisinhibitionDrug Delivery SystemsDysautonomiasEndocrineExperimental ModelsFDA approvedFailureFunctional disorderGangliaGeneticGoalsHost DefenseImmuneImmune systemImmunologic Deficiency SyndromesImmunosuppressionImpairmentIndividualInfectionInfection preventionInjuryInterventionLesionLifeLungLymphocyte CountLymphoid TissueLymphopeniaMethodologyMolecular TargetMulticenter StudiesNerveNeurologicNeuronsNeurosecretory SystemsNosocomial pneumoniaOutcomePathogenesisPathologicPatientsPharmaceutical PreparationsPneumoniaPredispositionPreventionQualifyingRecoveryRecovery of FunctionReflex actionRegimenRiskRisk FactorsSepsisSeriesSeveritiesSiteSpinalSpinal cord injurySpinal cord injury patientsSpleenStreptococcus pneumoniaeSympathetic Nerve BlockSynaptic TransmissionT-LymphocyteTechnologyTestingThymus GlandTissuesVertebral columnWhole Bloodadverse outcomecholinergicclinical applicationclinically relevantdisabilitydrug repurposingexperimental studygabapentingut dysbiosisimmune functionimmune system functionimprovedin vivoinsightmodifiable riskmortalityneurological recoveryneuroregulationnovelpharmacologicpresynapticpreventrestorationseptictransmission processtreatment strategyvoltage
项目摘要
Abstract
Acquired infections after spinal cord injury (SCI) are prevalent, constitute the main cause of death in patients
and have been identified as a modifiable risk factor associated with poor neurological and functional recovery.
Infection treatment by orthodox antibiotics is complicated by i) spectrum/efficacy gaps, ii) early development of
antibiotic resistancies, and iii) failure of antibiotics to prevent infections when applied early in patients with
acute CNS lesions. Moreover, new evidence indicates that antibiotics can impair neurological recovery, due to
their ability to cause gut dysbiosis. Improved anti-infective treatment strategies are critically needed, which take
the immune-compromised status after SCI into account. Recent data have identified unregulated sympathetic
tone originating from below the spinal cord injury site (spinally generated sympathetic nerve activity, SNA) as a
major driver of the systemic spinal cord injury immune deficiency syndrome (SCI-IDS). SNA has been
identified and independently confirmed as a mechanistic target to restore immune function in vivo. Three aims
are proposed to answer one main and novel question: Can immune function and host-defense against
pneumonia be re-established with SNA-targeting immunotrophic pharmacological neuromodulation (IPN)?
Experiments in Aim 1 will use a novel combination of FDA-approved drugs selected to promote immune
system function and reduce susceptibility to bacterial pneumonia acutely or at 4 weeks post SCI. Aim 2 will
assess the capacity of IPN to normalize different cellular SCI-IDS characteristics and the sympathetic
neuroendocrine reflex. Irrespective of SCI, infections are well-known causes of dysautonomia, which is a
pathophysiological conduit for septic conversions. Aim 3 addresses whether IPN can blunt infection-associated
autonomic dysfunction and neutralize a sepsis risk factor. If successful, data from these experiments will
directly inform effective non-antibiotic anti-infective strategies for SCI patients to reduce infection-associated
mortality and disability.
抽象的
脊髓损伤后获得的感染(SCI)普遍存在,构成患者的主要原因
并被确定为与不良神经和功能恢复相关的可修改风险因素。
正统抗生素的感染治疗因i)频谱/功效差距而复杂,ii)早期发展
在
急性中枢神经系统病变。此外,新的证据表明抗生素会损害神经系统恢复
它们引起肠道营养不良的能力。迫切需要改善的反感染治疗策略,这需要
SCI后的免疫功能障碍状态。最近的数据已经确定了不受管制的同情心
音调起源于脊髓损伤部位下方(旋转产生的交感神经活动,SNA)
全身性脊髓损伤免疫缺陷综合征(SCI-IDS)的主要驱动力。 SNA曾经
鉴定并独立确认为恢复体内免疫功能的机械靶标。三个目标
提议回答一个主要和新颖的问题:可以免疫功能和宿主防御
通过靶向SNA的免疫营养性神经调节(IPN)重新建立肺炎?
AIM 1中的实验将使用选择促进免疫的FDA批准药物的新型组合
系统功能并降低对细菌性肺炎的敏感性急性或科学后4周。 AIM 2意志
评估IPN标准化不同细胞SCI-IDS特征和交感神经的能力
神经内分泌反射。不论SCI如何,感染都是动作障碍的众所周知的原因,这是
化粪池转化的病理生理导管。 AIM 3解决了IPN是否可以钝化感染相关
自主功能障碍并中和败血症的危险因素。如果成功,这些实验的数据将
直接告知SCI患者有效的非抗生素抗感染策略,以减少与感染相关的
死亡率和残疾。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inhibition of the Nogo-pathway in experimental spinal cord injury: a meta-analysis of 76 experimental treatments.
- DOI:10.1038/s41598-023-49260-5
- 发表时间:2023-12-21
- 期刊:
- 影响因子:4.6
- 作者:Hirt, Julian;Khanteymoori, Alireza;Hohenhaus, Marc;Kopp, Marcel A.;Howells, David W.;Schwab, Jan M.;Watzlawick, Ralf
- 通讯作者:Watzlawick, Ralf
Bladder Management With Chronic Indwelling Catheter is Associated with Elevated Mortality in Patients with Spinal Cord Injury.
慢性留置导管的膀胱管理与脊髓损伤患者死亡率升高相关。
- DOI:10.1016/j.urology.2022.01.050
- 发表时间:2022
- 期刊:
- 影响因子:2.1
- 作者:Baradaran,Nima;Peng,Juan;Palettas,Marilly;Chen,YuYing;DeVivo,MichaelJ;Schwab,JanM
- 通讯作者:Schwab,JanM
Lesional Antibody Synthesis and Complement Deposition Associate With De Novo Antineuronal Antibody Synthesis After Spinal Cord Injury.
- DOI:10.1212/nxi.0000000000200099
- 发表时间:2023-05
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Dynamic induction of the myelin-associated growth inhibitor Nogo-A in perilesional plasticity regions after human spinal cord injury.
- DOI:10.1111/bpa.13098
- 发表时间:2023-01
- 期刊:
- 影响因子:6.4
- 作者:Schwaiger, Carmen;Haider, Thomas;Endmayr, Verena;Zrzavy, Tobias;Gruber, Victoria E.;Ricken, Gerda;Simonovska, Anika;Hametner, Simon;Schwab, Jan M.;Hoeftberger, Romana
- 通讯作者:Hoeftberger, Romana
A critical reappraisal of corticospinal tract somatotopy and its role in traumatic cervical spinal cord syndromes.
对皮质脊髓束躯体形态及其在创伤性颈脊髓综合征中的作用的批判性重新评估。
- DOI:10.3171/2021.7.spine21546
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Levi,AllanD;Schwab,JanM
- 通讯作者:Schwab,JanM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jan Schwab其他文献
Jan Schwab的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jan Schwab', 18)}}的其他基金
Reducing Infection Susceptibility by Immune Function Restoration in Spinal Cord Injury
通过恢复脊髓损伤的免疫功能来降低感染易感性
- 批准号:
10034001 - 财政年份:2020
- 资助金额:
$ 36.76万 - 项目类别:
Reducing Infection Susceptibility by Immune Function Restoration in Spinal Cord Injury
通过恢复脊髓损伤的免疫功能来降低感染易感性
- 批准号:
10226234 - 财政年份:2020
- 资助金额:
$ 36.76万 - 项目类别:
Reducing Infection Susceptibility by Immune Function Restoration in Spinal Cord Injury
通过恢复脊髓损伤的免疫功能来降低感染易感性
- 批准号:
10454352 - 财政年份:2020
- 资助金额:
$ 36.76万 - 项目类别:
相似国自然基金
影像组学用于急性病毒性肺炎鉴别诊断的生物学机制探究
- 批准号:82172029
- 批准年份:2021
- 资助金额:55.00 万元
- 项目类别:面上项目
影像组学用于急性病毒性肺炎鉴别诊断的生物学机制探究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
基于芳香药性的中药挥发油单体成分优化配伍治疗病毒性肺炎急性渗出期病理阶段的功效及作用机制研究
- 批准号:82141217
- 批准年份:2021
- 资助金额:67 万元
- 项目类别:专项基金项目
中西医综合治疗气分阶段非典型性肺炎的机理探讨
- 批准号:30340017
- 批准年份:2003
- 资助金额:25.0 万元
- 项目类别:专项基金项目
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 36.76万 - 项目类别:
MLL1 drives collaborative leukocyte-endothelial cell signaling and thrombosis after coronavirus infection
MLL1在冠状病毒感染后驱动白细胞-内皮细胞信号传导和血栓形成
- 批准号:
10748433 - 财政年份:2023
- 资助金额:
$ 36.76万 - 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10600887 - 财政年份:2023
- 资助金额:
$ 36.76万 - 项目类别:
LOX-1 as a protective countermeasure in response to lung infection
LOX-1 作为应对肺部感染的保护性对策
- 批准号:
10677924 - 财政年份:2023
- 资助金额:
$ 36.76万 - 项目类别:
The Intermountain West-Atlantic Center (InterACT) for the APS Phenotyping Consortium
APS 表型联盟的山间西大西洋中心 (InterACT)
- 批准号:
10649343 - 财政年份:2023
- 资助金额:
$ 36.76万 - 项目类别: